Cargando…

Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice

AIMS/HYPOTHESIS: Obesity is strongly associated with the development of non-alcoholic fatty liver disease (NAFLD). The cytokine osteopontin (OPN) was recently shown to be involved in obesity-induced adipose tissue inflammation and reduced insulin response. Accumulating evidence links OPN to the path...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiefer, F. W., Neschen, S., Pfau, B., Legerer, B., Neuhofer, A., Kahle, M., Hrabé de Angelis, M., Schlederer, M., Mair, M., Kenner, L., Plutzky, J., Zeyda, M., Stulnig, T. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131508/
https://www.ncbi.nlm.nih.gov/pubmed/21562757
http://dx.doi.org/10.1007/s00125-011-2170-0
_version_ 1782207720953217024
author Kiefer, F. W.
Neschen, S.
Pfau, B.
Legerer, B.
Neuhofer, A.
Kahle, M.
Hrabé de Angelis, M.
Schlederer, M.
Mair, M.
Kenner, L.
Plutzky, J.
Zeyda, M.
Stulnig, T. M.
author_facet Kiefer, F. W.
Neschen, S.
Pfau, B.
Legerer, B.
Neuhofer, A.
Kahle, M.
Hrabé de Angelis, M.
Schlederer, M.
Mair, M.
Kenner, L.
Plutzky, J.
Zeyda, M.
Stulnig, T. M.
author_sort Kiefer, F. W.
collection PubMed
description AIMS/HYPOTHESIS: Obesity is strongly associated with the development of non-alcoholic fatty liver disease (NAFLD). The cytokine osteopontin (OPN) was recently shown to be involved in obesity-induced adipose tissue inflammation and reduced insulin response. Accumulating evidence links OPN to the pathogenesis of NAFLD. Here we aimed to identify the role of OPN in obesity-associated hepatic steatosis and impaired hepatic glucose metabolism. METHODS: Wild-type (WT) and Opn (also known as Spp1) knockout (Opn (−/−)) mice were fed a high-fat or low-fat diet to study OPN effects in obesity-driven hepatic alterations. RESULTS: We show that genetic OPN deficiency protected from obesity-induced hepatic steatosis, at least in part, by downregulating hepatic triacylglycerol synthesis. Conversely, absence of OPN promoted fat storage in adipose tissue thereby preventing the obesity-induced shift to ectopic fat accumulation in the liver. Euglycaemic–hyperinsulinaemic clamp studies revealed that insulin resistance and excess hepatic glucose production in obesity were significantly attenuated in Opn (−/−) mice. OPN deficiency markedly improved hepatic insulin signalling as shown by enhanced insulin receptor substrate-2 phosphorylation and prevented upregulation of the major hepatic transcription factor Forkhead box O1 and its gluconeogenic target genes. In addition, obesity-driven hepatic inflammation and macrophage accumulation was blocked by OPN deficiency. CONCLUSIONS/INTERPRETATION: Our data strongly emphasise OPN as mediator of obesity-associated hepatic alterations including steatosis, inflammation, insulin resistance and excess gluconeogenesis. Targeting OPN action could therefore provide a novel therapeutic strategy to prevent obesity-related complications such as NAFLD and type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-011-2170-0) contains supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-3131508
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31315082011-08-10 Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice Kiefer, F. W. Neschen, S. Pfau, B. Legerer, B. Neuhofer, A. Kahle, M. Hrabé de Angelis, M. Schlederer, M. Mair, M. Kenner, L. Plutzky, J. Zeyda, M. Stulnig, T. M. Diabetologia Article AIMS/HYPOTHESIS: Obesity is strongly associated with the development of non-alcoholic fatty liver disease (NAFLD). The cytokine osteopontin (OPN) was recently shown to be involved in obesity-induced adipose tissue inflammation and reduced insulin response. Accumulating evidence links OPN to the pathogenesis of NAFLD. Here we aimed to identify the role of OPN in obesity-associated hepatic steatosis and impaired hepatic glucose metabolism. METHODS: Wild-type (WT) and Opn (also known as Spp1) knockout (Opn (−/−)) mice were fed a high-fat or low-fat diet to study OPN effects in obesity-driven hepatic alterations. RESULTS: We show that genetic OPN deficiency protected from obesity-induced hepatic steatosis, at least in part, by downregulating hepatic triacylglycerol synthesis. Conversely, absence of OPN promoted fat storage in adipose tissue thereby preventing the obesity-induced shift to ectopic fat accumulation in the liver. Euglycaemic–hyperinsulinaemic clamp studies revealed that insulin resistance and excess hepatic glucose production in obesity were significantly attenuated in Opn (−/−) mice. OPN deficiency markedly improved hepatic insulin signalling as shown by enhanced insulin receptor substrate-2 phosphorylation and prevented upregulation of the major hepatic transcription factor Forkhead box O1 and its gluconeogenic target genes. In addition, obesity-driven hepatic inflammation and macrophage accumulation was blocked by OPN deficiency. CONCLUSIONS/INTERPRETATION: Our data strongly emphasise OPN as mediator of obesity-associated hepatic alterations including steatosis, inflammation, insulin resistance and excess gluconeogenesis. Targeting OPN action could therefore provide a novel therapeutic strategy to prevent obesity-related complications such as NAFLD and type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-011-2170-0) contains supplementary material, which is available to authorised users. Springer-Verlag 2011-05-12 2011 /pmc/articles/PMC3131508/ /pubmed/21562757 http://dx.doi.org/10.1007/s00125-011-2170-0 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Kiefer, F. W.
Neschen, S.
Pfau, B.
Legerer, B.
Neuhofer, A.
Kahle, M.
Hrabé de Angelis, M.
Schlederer, M.
Mair, M.
Kenner, L.
Plutzky, J.
Zeyda, M.
Stulnig, T. M.
Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title_full Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title_fullStr Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title_full_unstemmed Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title_short Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
title_sort osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131508/
https://www.ncbi.nlm.nih.gov/pubmed/21562757
http://dx.doi.org/10.1007/s00125-011-2170-0
work_keys_str_mv AT kieferfw osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT neschens osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT pfaub osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT legererb osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT neuhofera osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT kahlem osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT hrabedeangelism osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT schledererm osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT mairm osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT kennerl osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT plutzkyj osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT zeydam osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice
AT stulnigtm osteopontindeficiencyprotectsagainstobesityinducedhepaticsteatosisandattenuatesglucoseproductioninmice